LYELL IMMUNOPHARMA INC's ticker is LYEL and the CUSIP is 55083R104. A total of 95 filers reported holding LYELL IMMUNOPHARMA INC in Q4 2022. The put-call ratio across all filers is 0.74 and the average weighting 0.9%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $29,638,628 | -53.8% | 20,162,332 | 0.0% | 28.72% | -25.9% |
| Q2 2023 | $64,116,216 | +34.7% | 20,162,332 | 0.0% | 38.79% | +15.8% |
| Q1 2023 | $47,583,104 | -32.0% | 20,162,332 | 0.0% | 33.50% | -6.2% |
| Q4 2022 | $69,963,292 | -52.7% | 20,162,332 | 0.0% | 35.72% | -37.3% |
| Q3 2022 | $147,790,000 | +12.4% | 20,162,332 | 0.0% | 56.93% | -3.7% |
| Q2 2022 | $131,458,000 | +29.1% | 20,162,332 | 0.0% | 59.13% | +37.2% |
| Q1 2022 | $101,820,000 | -34.8% | 20,162,332 | 0.0% | 43.09% | -5.3% |
| Q4 2021 | $156,056,000 | -48.1% | 20,162,332 | -0.7% | 45.49% | +24.9% |
| Q3 2021 | $300,418,000 | -9.0% | 20,298,522 | -0.2% | 36.43% | +12.3% |
| Q2 2021 | $330,147,000 | – | 20,329,235 | – | 32.44% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| MWG Management Ltd. | 20,162,332 | $69,963,292 | 35.72% |
| Orland Properties Ltd | 15,093,969 | $52,376,072 | 27.91% |
| Foresite Capital Management IV, LLC | 10,000,000 | $34,700,000 | 14.82% |
| MIC Capital Management UK LLP | 3,060,569 | $10,620,174 | 2.10% |
| Alphabet Inc. | 5,865,125 | $20,351,984 | 1.18% |
| HSG Holding Ltd | 3,045,997 | $10,569,610 | 1.07% |
| Artal Group S.A. | 700,000 | $2,429 | 0.14% |
| Eagle Health Investments LP | 100,000 | $347,000 | 0.08% |
| Virtus ETF Advisers LLC | 39,345 | $136,527 | 0.07% |
| BBR PARTNERS, LLC | 164,041 | $569,222 | 0.06% |